Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.57 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.56 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.51 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859707 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL21346930 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL9618051 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL10781130 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL21141423 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL10630367 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL15966827 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL10781198 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL9632719 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 | |
| SCHEMBL9615790 | 1.00 | LPAR3 (0.57) | LPAR3LPAR1LPAR2SGPL1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | LPAR3 2785/4885LPAR1 2018/4885LPAR2 2507/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | LPAR3 2785/4885LPAR1 2018/4885LPAR2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.